U.S. commission warns China could dominate drug development by 2030
A federal commission formed to study biotechnology competition between the U.S. and China has warned lawmakers to act quickly, according to Healthcare Dive. The commission said the U.S. risks becoming overly dependent on China for new medicines, which could leave American patients vulnerable to supply chain problems.
China has set a goal to produce a quarter of the world's first-in-class drugs by 2030, Healthcare Dive reported. The commission, an 11-member group that includes members of Congress, was created by defense appropriations legislation in 2022 to study biotech competition and promote supporting legislation.
The commission focused on cross-border licensing deals between U.S. and Chinese companies, Healthcare Dive reported. These deals increasingly involve preclinical research and signal growing confidence in China's ability to innovate in pharmaceuticals. The commission warned that such deals could transfer key knowledge to Chinese partners about how to develop and commercialize drugs for U.S. markets.
The commission chair stated that U.S.-China pharma deals are starting to favor Chinese startups, which risks reducing biotech research and development in the U.S., according to Healthcare Dive. The commission compared this pattern to what happened in the automobile, semiconductor, and industrial chemical sectors, where Chinese industry gained competitive advantage and later controlled global markets.
What it means in Raleigh
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Partners Health Management, Trillium Health Resources, Vaya Health.
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.